• 🌎 Worldwide
    • 🇺🇸 U.S.
    • 🇨🇦 Canada
    • 🇬🇧 United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Investments Press Releases

Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

Companies to Found New Company to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Disorders

PR Newswire by PR Newswire
March 6, 2019
in Health, Investments, Marijuana Stocks, Press Releases, United States
Cannabis Stock Deal News

Photo Credit - Cytonn Photography via Unsplash

52
SHARES
ShareShare

BETHESDA, Maryland and TEL AVIV, Israel, March 6, 2019 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has closed an agreement with Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases, to form a equally owned joint venture (JV) which will focus on the research and development of cannabinoid based treatments for ophthalmic disorders.

Initially announced in a press release on June 29, 2018, and then on February 7, 2019, the two companies have obtained an expert opinion which they believe identifies a potential route with the U.S. Food and Drug Administration for an ophthalmic therapy containing cannabinoids. Pursuant to the JV agreement signed on February 7, 2019, the successful completion of the above marks the initial closing of the agreement and the commencement of the JV, subject to the formation of the JV entity and the completion of a mutually agreeable business plan.

“We believe that the closing of this agreement emphasizes the potential embodied in cannabinoid-based therapies which can be used to treat ophthalmic disorders. The agreement supports our vision which is to bring cannabinoid-based therapies to modern medicine, which may be used as treatments for a wide variety of conditions,” said Eyal Barad, Cannabics’ CEO and Co-Founder.

“We are pleased to leverage our team and know-how as well as our lab and R&D license to support such joint ventures and we will continue to explore additional conditions, whereby patients may also benefit from cannabinoid-based therapies”.

About Wize Pharma, Inc. 
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (“DES”). Wize Pharma has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (“CCH”) and Sjögren’s Syndrome. Wize Pharma has finished a Phase II trial of LO2A for patients with CCH and currently conducting a Phase IV study for LO2A for DES in patients with Sjögren’s. LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCH and Sjögren’s, and in the Netherlands for the treatment of DES and Sjögren’s. Wize Pharma’s strategy involves engaging local or multinational distributors to handle the distribution of LO2A.

About Cannabics Pharmaceuticals  
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.

For the latest updates on Cannabics Pharmaceuticals follow the company on Twitter @cannabics1, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Forward Looking Statements   

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. For example, we are using forward-looking statements when we discuss the formation of the JV and the agreement and timing of a business plan, the belief that the expert opinion identifies a potential route with the FDA for an ophthalmic therapy containing cannabinoids,, the parties’ intention to launch a JV that intends to pursue cannabinoid-based compositions which can benefit patients who suffer from ophthalmic disorder indications and the belief that the introduction of cannabinoid-based therapies to modern medicine may be used as treatments for a wide variety of conditions. The statements in this release are based upon the current beliefs and expectations of Wize Pharma and Cannabics’ management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, the parties’ ability to license and protect their intellectual property, the parties’ ability to raise additional capital in the future that is necessary to maintain their respective businesses, changes in government policy and/or regulation, potential litigation by or against either party, any governmental review of the parties’ products or practices, as well as other risks discussed from time to time in each of Wize Pharma and Cannabics’ filings with the Securities and Exchange Commission. Wize Pharma and Cannabics undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: Cannabics Pharmaceuticals Inc.OTC:CNBXOTC:WIZPU.S. Food and Drug AdministrationWize Pharma Inc.

Get Real-Time Updates from MJobserver.com

Unsubscribe
PR Newswire

PR Newswire

PR Newswire empowers communicators to identify and engage with key influencers, craft and distribute meaningful stories, and measure the financial impact of their efforts. Cision is a leading global provider of earned media software and services to public relations and marketing communications professionals.

Related Posts

Marinol Dronabinol THC Pharmaceutical
Events

30+ Expert Speakers to Present at the 3rd Annual Cannabinoid-Derived Pharmaceuticals Summit

July 9, 2020
FDA Cannabis and CBD News
Press Releases

Charlotte’s Web Steps Up to Support Research to Address FDA’s Request for More Scientific Data

June 9, 2020
Submitting a Comment to the FDA on CBD in Foods and Beverages
Health

Tetra Receives its 4th FDA Orphan Drug Designation

April 16, 2020
Marijuana Stocks - Gainers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Gainers – Tuesday, December 17, 2019

December 17, 2019
Marijuana Stocks - Gainers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Gainers – Tuesday, November 26, 2019

November 26, 2019
Marijuana Stocks - Gainers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Gainers – Monday, November 25, 2019

November 25, 2019
Load More
Next Post
Emblem Corp. Shareholders Approve Proposed Arrangement with Aleafia Health, Announces Results of Special Meeting

Emblem Corp. Shareholders Approve Proposed Arrangement with Aleafia Health, Announces Results of Special Meeting

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

🚨 Subscribe to Stock Alerts

Get Live Updates on Breaking News

Subscribe Now

✉️ Subscribe to Our Newsletter!

* indicates required

🔎 Search Marijuana Stocks

📰 Recent News

  • Aleafia Health Launches Everyday Cannabis Brand Divvy
  • Green Thumb Industries Expands Independent Governance with Appointment of Swati Mylavarapu to Board of Directors
  • Healixa Inc. Appoints Kealy Altman as Vice President of Marketing
  • MediPharm Labs Achieves Export Milestone, Ships Cannabis Oil from Australia to Germany
  • Verano Holdings Shares Approved to Trade on OTC Markets Under the Symbol VRNOF
Facebook Twitter Instagram LinkedIn Youtube

Cannabis News by Region

  • 🇺🇸 United States
  • 🇨🇦 Canada
  • 🇬🇧 United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Cannabis Tools & Resources

  • 📅 Calendar
  • 📊 Databases
  • 📇 Directories
  • 🔔 RSS Feeds
  • 📺 Videos

Find Cannabis Business Services

  • ⚖️ Attorneys & Law Firms
  • 📊 Accountants & Accounting Firms
  • 💡 Consultants & Consulting Firms
  • 📲 Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • 👀 Advertise
  • 📣 DMO Newswire
  • 📇 List in Our Databases

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • 🔒 PRO
    • 🔒 A.M. Watchlist
    • 🔒 Analyst Action
  • 💼 Business
  • 📈 Investments
    • 📈 Stocks
    • 💰 ETFs and Funds
    • 💭 Market Commentary
    • 📰 Press Releases
    • 📅 Earnings Calendar
  • ⚖️ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • 👥 People
    • ⚽ Athletes
    • 💼 Executives
    • 🌟 Celebrities
    • 🛒 Consumers
    • ⚕️ Doctors
    • 💊 Patients
  • 💊 Health
  • 📇 Databases
    • 📈 Stock Databases
    • 💰 Fund Databases
    • 💼 Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • 💲 Marijuana Cryptocurrencies

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.